Meihua International Medical Technologies Co., Ltd. announced the appointment of Mr. Xin Wang as Chief Executive Officer and director, effective as of December 1, 2022, to fill the vacancy arising from the voluntary resignations of Mr. Yulin Wang as CEO, interim CFO and director of the Company due to the expiration of his employment contract. Prior to joining MHUA, from 2021 until 2022, Mr. Xin Wang was CEO of the Jiangsu Yada Technology Group Co., Ltd., a PRC company that develops and distributes medical devices. In addition, Mr. Wang served as Vice General Manager of Shanghai New Asia (Group) Co., Ltd., a pharmaceutical company, where he led production management, market expansion, research and development of proprietary Chinese traditional medicines from 2020 to 2021.

From 2018 to 2020, Mr. Wang held key position at Panda Group Inc., a franchise restaurant corporation based in California, where he was in charge of large commercial projects related to expanding its business operations and upgrading its brand strategy in the US market. In addition, Mr. Wang worked as a financial analyst at Morgan Stanley and area manager at Citibank, N.A., thus providing him insight into global investment banking and US financial markets. Mr. Wang obtained his bachelor's degree from the University of California Santa Barbara, where he double majored in Financial Mathematics & Statistics Analysis and Computer Science.

He also obtained his master's degree in Actuarial Science in 2012 from UC Santa Barbara.